未登录

E

E. Galmozzi

university of milan

H指数:22

被引数:3,236

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs

肝脏脂肪遗传风险评分预测用DAAs治疗的肝硬化HCV患者的肝细胞癌

IF15.8

2020-11-2054

OAAI

Letter to the Editor: Does the HSD17B13 rs72613567 Splice Variant Actually Yield a New Type of Alternative Splicing?

IF15.8

2020-04-290

PREAI

Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated hbv cirrhotics treated with nuc for 10 years

DIGESTIVE AND LIVER DISEASE

IF3.8

2020-02-010

PREAI

The HSD17B13 rs6834314 variant is associated with liver stiffness measurement in untreated HCV-3 patients with cirrhosis

DIGESTIVE AND LIVER DISEASE

IF3.8

2020-02-010

PREAI

A genetic risk score predicts de novo hepatocellular carcinoma in hepatits c cirrhotic patients treated with direct-acting antivirals

DIGESTIVE AND LIVER DISEASE

IF3.8

2020-02-010

PREAI

AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma

JOURNAL OF HEPATOLOGY

IF33

2019-04-010

PREAI

The development of hepatolocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years

DIGESTIVE AND LIVER DISEASE

IF3.8

2019-02-010

PREAI

Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients

DIGESTIVE AND LIVER DISEASE

IF3.8

2019-02-011

PREAI

AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma

DIGESTIVE AND LIVER DISEASE

IF3.8

2019-02-010

PREAI

Nonalcoholic fatty liver disease: is the IFNL4 rs368234815 variant protective from liver damage?

HEPATOBILIARY SURGERY AND NUTRITION

IF7.8

2018-06-011

OAAI

National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

JOURNAL OF HEPATOLOGY

IF33

2018-04-010

PREAI

Ruggiero, T.; Cento, V.; Aragri, M.; Arosio, M.; Baldanti, F.; Brunetto, M.; Bruzzone, B.; Boeri, E.; Cavallone, D.; Nicola, C.; Stefano, M. A. D.; Ghisetti, V.; Callegaro, M. P.; Capobianchi, M. R.; Caudai, C.; Cuomo, N.; Galli, S.; Galmozzi, E.; Garbuglia, A.; Gennari, W.; Lai, A.; Menzo, S.; Micheli, V.; Minosse, C.; Monno, L.; Paolucci, S.; Pollicino, T.; Raddi, A.; Raffa, G.; Raimondo, G.; Sanguinetti, M.; Santangelo, R.; Santantonio, T.; Soldini, S.; Starace, M.; Vatteroni, M. L.; Craxi, A.; Perno, C. F.; Silberstein, F. C.; Zazzi, M.

TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens

JOURNAL OF HEPATOLOGY

IF33

2018-04-010

PREAI

National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

DIGESTIVE AND LIVER DISEASE

IF3.8

2018-02-011

PREAI

Ruggiero, T.; Cento, V.; Aragri, M.; Arosio, M.; Baldanti, F.; Brunetto, M.; Bruzzone, B.; Boeri, E.; Cavallone, D.; Coppola, N.; Di Stefano, M.; Ghisetti, V.; Callegaro, A. P.; Capobianchi, M. R.; Caudai, C.; Cuomo, N.; Galli, S.; Galmozzi, E.; Garbuglia, A. R.; Gennari, W.; Lai, A.; Menzo, S.; Micheli, V.; Minosse, C.; Monno, L.; Paolucci, S.; Pollicino, T.; Raddi, A.; Raffa, G.; Raimondo, G.; Sanguinetti, M.; Sampaolo, M.; Santangelo, R.; Santantonio, T.; Soldini, S.; Starace, M.; Vatteroni, M. L.; Craxi, A.; Perno, C. F.; Ceccherini-Silberstein, F.; Zazzi, M.

Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years

DIGESTIVE AND LIVER DISEASE

IF3.8

2018-02-011

PREAI

Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting

DIGESTIVE AND LIVER DISEASE

IF3.8

2018-02-010

PREAI

Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance

替诺福韦艾拉酚胺作为具有Fanconi综合征和多药耐药性病史的HBV肝硬化患者的抢救治疗

JOURNAL OF HEPATOLOGY

IF33

2018-01-0121

PREAI

IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients

IFNL4 rs368234815和rs117648444变体预测IFN治疗的HBeAg阴性慢性乙型肝炎患者的HBsAg血清清除

LIVER INTERNATIONAL

IF5.2

2017-08-1010

PREAI

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B

JOURNAL OF HEPATOLOGY

IF33

2017-05-01124

PREAI

High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients

DIGESTIVE AND LIVER DISEASE

IF3.8

2017-02-010

PREAI

Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B

DIGESTIVE AND LIVER DISEASE

IF3.8

2017-02-010

PREAI